The role of Galectin-3 in α-synuclein-induced microglial activation

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Boza Serrano, Antonio ^a   Reyes, Juan F ^a   Rey, Nolwen L ^a,b   Leffler, Hakon ^a   Bousset, Luc ^e   Nilsson, Ulf ^a   Brundin, Patrik ^a,b   Venero, Jose Luis ^d   Burguillos, Miguel Angel ^c   Deierborg, Tomas ^a  

^a LUND UNIVERSITY   (Sweden)

^b VAN ANDEL INSTITUTE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF SEVILLE   (Spain)

^e LABORATOIRE D ENZYMOLOGIE ET BIOCHIMIE STRUCTURALES   (France)

Author keywords

Galectin 3; Microglia; Neuroinflammation; Parkinson's disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; GALECTIN 3; IL1B PROTEIN, MOUSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 1BETA; LGALS3 PROTEIN, MOUSE; NOS2 PROTEIN, MOUSE; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; SNCA PROTEIN, MOUSE;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; KNOCKOUT MOUSE; METABOLISM; MICROGLIA; MOUSE; OLFACTORY BULB; PHAGOCYTOSIS; PHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GALECTIN 3; INTERLEUKIN-12; INTERLEUKIN-1BETA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; NEUROIMMUNOMODULATION; NITRIC OXIDE SYNTHASE TYPE II; OLFACTORY BULB; PHAGOCYTOSIS; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING;

EID: 84964697525     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-014-0156-0     Document Type: Review

References (71)

1. Chaudhuri KR, Schapira AH: Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8: 464-474. 10.1016/S1474-4422(09)70068-7
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature 1997, 388: 839-840. 10.1038/42166
3. Qiao S, Luo JH, Jin JH: Role of microglial activation induced by alpha-synuclein in pathogenesis of Parkinson's disease. Zhejiang Da Xue Xue Bao Yi Xue Ban 2012, 41: 210-214.
4. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ: Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 2008, 63: 743-750. 10.1002/ana.21380
5. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998, 18: 106-108. 10.1038/ng0298-106
6. George JM, Jin H, Woods WS, Clayton DF: Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995, 15: 361-372. 10.1016/0896-6273(95)90040-3
7. Stefanis L: alpha-Synuclein in Parkinson's disease. Cold Spring Harbor Perspect Med 2012, 2: a009399. 10.1101/cshperspect.a009399
8. Kholodilov NG, Neystat M, Oo TF, Lo SE, Larsen KE, Sulzer D, Burke RE: Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J Neurochem 1999, 73: 2586-2599. 10.1046/j.1471-4159.1999.0732586.x
9. Bendor JT, Logan TP, Edwards RH: The function of alpha-synuclein. Neuron 2013, 79: 1044-1066. 10.1016/j.neuron.2013.09.004
10. Shin EC, Cho SE, Lee DK, Hur MW, Paik SR, Park JH, Kim J: Expression patterns of alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental stages. Mol Cells 2000, 10: 65-70. 10.1007/s10059-000-0065-x
11. Lee HJ, Bae EJ, Lee SJ: Extracellular alpha-synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol 2014, 10: 92-98. 10.1038/nrneurol.2013.275
12. George S, Rey NL, Reichenbach N, Steiner JA, Brundin P: alpha-Synuclein: the long distance runner. Brain Pathol 2013, 23: 350-357. 10.1111/bpa.12046
13. Olanow CW, Brundin P: Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord 2013, 28: 31-40. 10.1002/mds.25373
14. Dunning CJ, George S, Brundin P: What's to like about the prion-like hypothesis for the spreading of aggregated alpha-synuclein in Parkinson disease? Prion 2013, 7: 92-97. 10.4161/pri.23806
15. Villar-Cheda B, Dominguez-Meijide A, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL: Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis 2012, 47: 268-279. 10.1016/j.nbd.2012.04.010
16. Tomas-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A, Venero JL: Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis 2004, 16: 190-201. 10.1016/j.nbd.2004.01.010
17. Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de Bernard M: Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One 2013, 8: e55375. 10.1371/journal.pone.0055375
18. Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, Lee SJ: Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 2013, 4: 1562. 10.1038/ncomms2534
19. Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, Wenning GK, Stefanova N: Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 2013, 61: 349-360. 10.1002/glia.22437
20. Rojanathammanee L, Murphy EJ, Combs CK: Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. J Neuroinflammation 2011, 8: 44. 10.1186/1742-2094-8-44
21. Gordon S, Pluddemann A: Tissue macrophage heterogeneity: issues and prospects. Semin Immunopathol 2013, 35: 533-540. 10.1007/s00281-013-0386-4
22. Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, Lachaud CC, Guilliams T, Fernandez-Montesinos R, Benitez-Rondan A, Robledo G, Hmadcha A, Delgado M, Pozo D: Preconditioning of microglia by alpha-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PloS one 2013, 8: e79160. 10.1371/journal.pone.0079160
23. De Pablos RM, Herrera AJ, Villaran RF, Cano J, Machado A: Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB J 2005, 19: 407-409.
24. Zindler E, Zipp F: Neuronal injury in chronic CNS inflammation. Best Pract Res Clin Anaesthesiol 2010, 24: 551-562. 10.1016/j.bpa.2010.11.001
25. Stirling DP, Cummins K, Mishra M, Teo W, Yong VW, Stys P: Toll-like receptor 2-mediated alternative activation of microglia is protective after spinal cord injury. Brain 2013, 137: 707-723. 10.1093/brain/awt341
26. Venero JL, Burguillos MA, Brundin P, Joseph B: The executioners sing a new song: killer caspases activate microglia. Cell Death Differ 2011, 18: 1679-1691. 10.1038/cdd.2011.107
27. Jiang HR, Al Rasebi Z, Mensah-Brown E, Shahin A, Xu D, Goodyear CS, Fukada SY, Liu FT, Liew FY, Lukic ML: Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol 2009, 182: 1167-1173. 10.4049/jimmunol.182.2.1167
28. Pajoohesh-Ganji A, Knoblach SM, Faden AI, Byrnes KR: Characterization of inflammatory gene expression and galectin-3 function after spinal cord injury in mice. Brain Res 2012, 1475: 96-105. 10.1016/j.brainres.2012.07.058
29. Seetharaman J, Kanigsberg A, Slaaby R, Leffler H, Barondes SH, Rini JM: X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J Biol Chem 1998, 273: 13047-13052. 10.1074/jbc.273.21.13047
30. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F: Introduction to galectins. Glycoconj J 2004, 19: 433-440. 10.1023/B:GLYC.0000014072.34840.04
31. Shin T: The pleiotropic effects of galectin-3 in neuroinflammation: a review. Acta Histochem 2013, 115: 407-411. 10.1016/j.acthis.2012.11.010
32. Jeon SB, Yoon HJ, Chang CY, Koh HS, Jeon SH, Park EJ: Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J Immunol 2010, 185: 7037-7046. 10.4049/jimmunol.1000154
33. Karlsson A, Christenson K, Matlak M, Bjorstad A, Brown KL, Telemo E, Salomonsson E, Leffler H, Bylund J: Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology 2009, 19: 16-20. 10.1093/glycob/cwn104
34. Lalancette-Hebert M, Swarup V, Beaulieu JM, Bohacek I, Abdelhamid E, Weng YC, Sato S, Kriz J: Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. J Neurosci 2012, 32: 10383-10395. 10.1523/JNEUROSCI.1498-12.2012
35. Lepur A, Carlsson MC, Novak R, Dumic J, Nilsson UJ, Leffler H: Galectin-3 endocytosis by carbohydrate independent and dependent pathways in different macrophage like cell types. Biochim Biophys Acta 1820, 2012: 804-818.
36. Liu FT, Rabinovich GA: Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci 2010, 1183: 158-182. 10.1111/j.1749-6632.2009.05131.x
37. Sano H, Hsu DK, Apgar JR, Yu L, Sharma BB, Kuwabara I, Izui S, Liu FT: Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest 2003, 112: 389-397. 10.1172/JCI200317592
38. Lee HJ, Suk JE, Bae EJ, Lee SJ: Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun 2008, 372: 423-428. 10.1016/j.bbrc.2008.05.045
39. Yang RY, Hsu DK, Liu FT: Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 1996, 93: 6737-6742. 10.1073/pnas.93.13.6737
40. Colnot C, Ripoche MA, Milon G, Montagutelli X, Crocker PR, Poirier F: Maintenance of granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology 1998, 94: 290-296. 10.1046/j.1365-2567.1998.00517.x
41. Doverhag C, Hedtjarn M, Poirier F, Mallard C, Hagberg H, Karlsson A, Savman K: Galectin-3 contributes to neonatal hypoxic-ischemic brain injury. Neurobiol Dis 2010, 38: 36-46. 10.1016/j.nbd.2009.12.024
42. Deierborg T: Preparation of primary microglia cultures from postnatal mouse and rat brains. Methods Mol Biol 2013, 1041: 25-31. 10.1007/978-1-62703-520-0_4
43. Grey M, Linse S, Nilsson H, Brundin P, Sparr E: Membrane interaction of alpha-synuclein in different aggregation states. J Parkinsons Dis 2011, 1: 359-371.
44. Saksida T, Nikolic I, Vujicic M, Nilsson UJ, Leffler H, Lukic ML, Stojanovic I, Stosic-Grujicic S: Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro. J Cell Physiol 2013, 228: 1568-1576. 10.1002/jcp.24318
45. Volarevic V, Milovanovic M, Ljujic B, Pejnovic N, Arsenijevic N, Nilsson U, Leffler H, Lukic ML: Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology 2012, 55: 1954-1964. 10.1002/hep.25542
46. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, Sethi T: Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012, 185: 537-546. 10.1164/rccm.201106-0965OC
47. Rey NL, Petit GH, Bousset L, Melki R, Brundin P: Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 2013, 126: 555-573. 10.1007/s00401-013-1160-3
48. Ghee M, Melki R, Michot N, Mallet J: PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly. FEBS J 2005, 272: 4023-4033. 10.1111/j.1742-4658.2005.04776.x
49. Henn A, Lund S, Hedtjarn M, Schrattenholz A, Porzgen P, Leist M: The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. Altex 2009, 26: 83-94.
50. Blandini F: Neural and immune mechanisms in the pathogenesis of Parkinson's disease. J Neuroimmune Pharmacol 2013, 8: 189-201. 10.1007/s11481-013-9435-y
51. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM: Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75: 1766-1772. 10.1212/WNL.0b013e3181fd613b
52. Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E: Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 2014, 62: 387-398. 10.1002/glia.22611
53. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ: Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012, 32: 13454-13469. 10.1523/JNEUROSCI.1292-12.2012
54. Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, Fernandez-Montesinos R, Caro M, Lachaud CC, Waudby CA, Delgado M, Dobson CM, Pozo D: Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants. PloS one 2010, 5: e13481. 10.1371/journal.pone.0013481
55. Spencer B, Michael S, Shen J, Kosberg K, Rockenstein E, Patrick C, Adame A, Masliah E: Lentivirus mediated delivery of neurosin promotes clearance of wild-type alpha-synuclein and reduces the pathology in an alpha-synuclein model of LBD. Mol Ther 2013, 21: 31-41. 10.1038/mt.2012.66
56. Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M: Neuroimmunological processes in Parkinson's disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 2013, 5: 113-139. 10.1042/AN20120066
57. Schwartz M, Kipnis J, Rivest S, Prat A: How do immune cells support and shape the brain in health, disease, and aging? J Neurosci 2013, 33: 17587-17596. 10.1523/JNEUROSCI.3241-13.2013
58. Suk K, Ock J: Chemical genetics of neuroinflammation: natural and synthetic compounds as microglial inhibitors. Inflammopharmacology 2012, 20: 151-158. 10.1007/s10787-011-0108-2
59. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, Hirakawa A, Takeuchi H, Suzumura A, Ishiguro N, Kadomatsu K: Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis 2013, 4: e525. 10.1038/cddis.2013.54
60. Surace MJ, Block ML: Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cell Mol Life Sci 2012, 69: 2409-2427. 10.1007/s00018-012-1015-4
61. Vafeiadou K, Vauzour D, Spencer JP: Neuroinflammation and its modulation by flavonoids. Endocr Metab Immune Disord Drug Targets 2007, 7: 211-224. 10.2174/187153007781662521
62. Delacour D, Koch A, Jacob R: The role of galectins in protein trafficking. Traffic 2009, 10: 1405-1413. 10.1111/j.1600-0854.2009.00960.x
63. Carlsson S, Carlsson MC, Leffler H: Intracellular sorting of galectin-8 based on carbohydrate fine specificity. Glycobiology 2007, 17: 906-912. 10.1093/glycob/cwm059
64. Kang BY, Kim E, Kim TS: Regulatory mechanisms and their therapeutic implications of interleukin-12 production in immune cells. Cell Signal 2005, 17: 665-673. 10.1016/j.cellsig.2004.12.010
65. Rothe H, Hartmann B, Geerlings P, Kolb H: Interleukin-12 gene-expression of macrophages is regulated by nitric oxide. Biochem Biophys Res Commun 1996, 224: 159-163. 10.1006/bbrc.1996.1000
66. Latz E, Xiao TS, Stutz A: Activation and regulation of the inflammasomes. Nat Rev Immunol 2013, 13: 397-411. 10.1038/nri3452
67. Strowig T, Henao-Mejia J, Elinav E, Flavell R: Inflammasomes in health and disease. Nature 2012, 481: 278-286. 10.1038/nature10759
68. Lee HM, Kang J, Lee SJ, Jo EK: Microglial activation of the NLRP3 inflammasome by the priming signals derived from macrophages infected with mycobacteria. Glia 2013, 61: 441-452. 10.1002/glia.22448
69. Hafner-Bratkovic I, Bencina M, Fitzgerald KA, Golenbock D, Jerala R: NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1beta and neuronal toxicity. Cell Mol Life Sci 2012, 69: 4215-4228. 10.1007/s00018-012-1140-0
70. Freeman D, Cedillos R, Choyke S, Lukic Z, McGuire K, Marvin S, Burrage AM, Sudholt S, Rana A, O'Connor C, Wiethoff CM, Campbell EM: Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 2013, 8: e62143. 10.1371/journal.pone.0062143
71. Sokolowski JD, Mandell JW: Phagocytic clearance in neurodegeneration. Am J Pathol 2011, 178: 1416-1428. 10.1016/j.ajpath.2010.12.051